No Data
No Data
Sector Update: Health Care
Health care stocks were mixed late Friday afternoon with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) adding 0.1%. The iShares Biotechnology ETF (IB
Marinus Completes Enrollment in Tuberous Sclerosis Complex Trial; Gets New Patent
Marinus Pharmaceuticals (MRNS) said Friday that it has completed enrollment in a phase 3 trial of oral ganaxolone for the treatment of seizures associated with tuberous sclerosis complex in children a
Here's Why Marinus Pharmaceuticals (MRNS) Is Poised for a Turnaround After Losing -7.8% in 4 Weeks
Buy Rating Affirmed: Marinus Pharmaceuticals' Advancements and Long-term Patent Protection Signal Strong Prospects
Marinus Pharmaceuticals Wraps Phase 3 Trial Enrollment for Tuberous Sclerosis Complex Treatment, Targets New Drug Application in 2025 Following Phase 3 Seizure Treatment Trial
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced completion of enrollment in th
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Just Reported, And Analysts Assigned A US$6.67 Price Target
As you might know, Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) last week released its latest first-quarter, and things did not turn out so great for shareholders. The numbers were weak, with reve